The Emerging Role of Sunitinib in the Treatment of Advanced Epithelial Thyroid Cancer: Our Experience and Review of Literature

Author(s): G. Pasqualetti, S. Ricci, A. Dardano, M. Ferdeghini, M. Del Tacca, F. Monzani

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 11 , Issue 9 , 2011

Become EABM
Become Reviewer
Call for Editor


Tyrosine kinase receptors have been shown to play an important role in epithelial thyroid tumor growth and angiogenesis. Thyroid cancers commonly present oncogene mutations involved in MAPK kinase pathway like BRAF and RET; they are also frequently dependent on VEGF stimuli. Preliminary clinical experiences suggest a promising role of sunitinib (a tyrosine kinase inhibitor) for the treatment of advanced thyroid cancers. This review deals with the available data on the effect of sunitinib in the treatment of metastatic, radioiodine refractory thyroid cancers. We also report our experience with the off-label use of sunitinib in such patients.

Keywords: Thyroid cancer, sunitinib, tyrosin-kinase inhibitor, metastatic disease, Tyrosine kinase receptors, epithelial thyroid tumor, angiogenesis, oncogene mutations, MAPK kinase, BRAF, RET, VEGF stimuli

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Published on: 01 March, 2012
Page: [746 - 752]
Pages: 7
DOI: 10.2174/138955711796355249
Price: $65

Article Metrics

PDF: 9